Key Takeaways
- A new long-acting HIV drug, lenacapavir, shows promise for annual dosing with sustained effectiveness.
- High drug levels persist in blood plasma, maintaining protection against HIV without the need for frequent injections.
- Gilead Sciences plans a phase III trial and is seeking approval from regulatory agencies for lenacapavir.
Innovative HIV Drug Shows Promising Results
Lenacapavir, a new HIV drug, demonstrates safe and potentially effective results in recent trials presented at the Conference on Retroviruses and Opportunistic Infections in San Francisco. The drug’s levels in blood plasma remain significantly higher than those needed for protection against HIV, even in individuals who received the lower dosage. Dr. Renu Singh, a senior director at Gilead Sciences, noted that these findings suggest the new annual injection could provide similar protection to the previously used twice-yearly shots.
Carina Marquez, an associate professor at the University of California, San Francisco, expressed enthusiasm over the results, emphasizing that transitioning to annual injections could simplify treatment for patients and healthcare providers, significantly reducing costs. The preliminary data from phase I trials shows promise for lenacapavir potentially becoming a “game changer” in HIV prevention.
Lenacapavir works by disrupting the virus’s replication process and possesses unique characteristics. It can be administered either daily or annually, with small doses maintaining therapeutic levels for several days. Larger doses create a depot effect, gradually releasing the drug over time. According to Dr. Singh, such properties make lenacapavir stand out among other molecules studied in the past.
Typically, a successful phase I trial leads to a phase II trial assessing a drug’s efficacy. However, lenacapavir’s remarkable results from previous trials mean that Gilead is now moving directly to a phase III trial, which will assess the drug’s effectiveness in a broader population at risk of HIV.
Although lenacapavir is not yet approved, Gilead has submitted the application for the twice-yearly version to the FDA and the European Medicines Agency (EMA), anticipating FDA approval by June. Additionally, the drug is undergoing evaluation through the EU-Medicines for All (EU-M4all) procedure, a collaborative effort aimed at expediting drug approvals for low- and middle-income countries.
Overall, lenacapavir’s promising trial results indicate a potential shift in HIV prevention, paving the way for more convenient treatment options for those at risk of HIV infection.
The content above is a summary. For more details, see the source article.